Marcin Bula

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Alasdair Munro, Shuo Feng, Leila Janani et al. · The Lancet Infectious Diseases · 2022 · 177 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Saye Khoo, Richard J. Fitzgerald, Sean Ewings et al. · Journal of Antimicrobial Chemotherapy · 2021 · 118 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Saye Khoo, Richard J. Fitzgerald, Geoffrey Saunders et al. · The Lancet Infectious Diseases · 2022 · 80 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

Xinxue Liu, Alasdair Munro, Shuo Feng et al. · Journal of Infection · 2022 · 66 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial

Ivan T. Lee, Catherine A. Cosgrove, Patrick Moore et al. · The Lancet Infectious Diseases · 2023 · 53 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16